Stryker MAKO Purchase Could Preview Ortho’s Future
This article was originally published in The Gray Sheet
Market-leading orthopedic firms have mostly come up with incremental product updates in response to the growing tide of more technology-heavy upstarts. That is what makes Stryker’s $1.65 billion acquisition of MAKO Surgical stand out.
You may also be interested in...
Israeli firm Insightec appoints former Mako Surgical co-founder and chair as CEO, ACell taps new president and CEO, and more personnel updates from JenaValve Technology, Zeltiq and Reva Medical.
Stryker advanced its robotic-assisted surgery opportunity with its 510(k) clearance to use its Mako system for total hip replacement surgeries. The large joint replacement manufacturer's long-term strategy is to make medical robotics that will be adopted by hospitals because their machines are compatible with different Stryker joints.
Stryker’s second-quarter sales figures paint the U.S. joint reconstruction market in a more positive light than some feared earlier in the month.